Based on evaluation of the currently available data and the Rapporteurs’ assessment reports, the CPMP considered that the benefit/ risk profile of loratadine containing medicinal products remains favourable, and therefore adopted an opinion on 20 November 2003 recommending that the Applications/ Marketing Authorisations for loratadine containing medicinal products should be granted or maintained in accordance with the SPC set out in Annex III of the Opinion. in the indication: “ relief of symptoms associated with Allergic Rhinitis and Chronic Idiopathic Urticaria”.